Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Pareesh Phulkar
pareesh@coherentmarketinsights.com
www.coherentmarketinsights.com/

Bookmark and Share
Apixaban Market status and Development Trends, Growth Drivers and Challenges 2018 -2026
Apixaban is indicated to reduce the risk of and systemic in patients with nonvalvular atrial fibrillation.


Apixaban Market
BriefingWire.com, 9/13/2019 - Apixaban is indicated to reduce the risk of and systemic in patients with nonvalvular atrial fibrillation. The recommended dose of Eliquis is 5mg orally twice a day. Apixaban is available in the market as capsules and tablet form.

Increasing prevalence of venous thrombo related conditions is expected to aid in growth of the apixaban market. For instance, according to International Society on Thrombosis and Haemostasis 2014 facts, revealed that around 10 million cases of venous thrombo occur annually across low, middle and high income countries.

Increasing therapeutic indications for apixaban is expected to boost the apixaban market growth. For instance, in 2014, the U.S. Food and Drug Administration approved Eliquis for the treatment of deep vein thrombosis (DVT) prophylaxis and pulmonary (PE) and also for the reduction in risk of recurrent PE and DVT following initial therapy. Furthermore, government and private organizations are significantly investing capital in healthcare research and development and this is also likely to propel growth of the Apixaban market.

Get PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/1898

According to GoodRx Inc. 2018 pricing detail, 60 tablets of Eliquis 5mg cost around US$ 524.38 on an average in the U.S. Moreover, increasing prevalence of venous thromboembolic events has boosted adoption of apixaban in North America market significantly. For instance, according to study published in the American Journal of Preventive Medicine in 2010, venous thrombo(VTE) affects approximately 300,000-600,000 people in the U.S. annually, causing considerable mortality. Furthermore, venous thrombo (VTE) disorder can occur in all ethnicities, all age groups, and both genders.

Moreover, a study published PLOS ONE 2016 showed, the cost effectiveness of apixaban drug versus warfarin in Chinese patients with non-valvular atrial fibrillation in Hong Kong are some the factors that are also propelling the growth of apixaban market in the particular region.

For instance, in 2016, Pfizer and Bristol-Myers Squibb entered into collaboration with Portola Pharmaceuticals to commercialize and develop investigational Andexanet Alfa, a clinical phase 3 drug, which is developed to reverse the anticoagulant effect of Factor Xa inhibitors that will be helpful for patients experience a major bleeding issue on the use of Eliquis.

Major players operating in the global apixaban market include Bristol-Myers Squibb, Portola Pharmaceuticals, C. H. Boehringer Sohn, Pfizer, Roche, CoaguSense, Siemens, Alere, and Abbott. Market players are focusing on developing new technologies, and on mergers, and collaborations in order to gain dominant position in the market.

Browse more detail information about: https://www.coherentmarketinsights.com/ongoing-insight/apixaban-market-1898

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2019 Proserve Technology, Inc.